Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Chugai’s Risdiplam Receives MHLW’s Orphan Drug Designation for Spinal Muscular

Shots: The MHLW’s ODD follows P-II/III (FIREFISH, SUNFISH) study assessing Risdiplam in patients with  spinal muscular atrophy (SMA) in Japan  Chugai & Roche collaborated for the clinical development Risdiplam, first oral systemic therapy for SMA Risdiplam (RG7916) is survival motor neuron-2 (SMN2) splicing modifier targeted to increase SMN protein levels in CNS and has received […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 25-29, 2019)

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders Published: March 29, 2019 | Tags: Takeda, Signs, Multi- Target Agreement, StrideBio, Develop, Gene Therapies, Neurological Diseases Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study Published: March 29, 2019 | Tags: Mitsubishi Tanabe Pharma, MTPA, Collaborates, Massachusetts […]Read More


Gilead’s Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives MHLW’s Approval

Shots: The approval is based on four P-III 1489 and 1490 & 1844 and 1878 studies result assessing Biktarvy vs PBO in 2,415 naive patients with HIV-1 infected & virologically suppressed adults respectively The P-III 1489 and 1490 & 1844 and 1878 studies results: @48wks. met its 1EPs; no treatment emergent virologic resistance; no discontinuation; […]Read More


Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext

Shots:  ImmuNext to receive $40M upfront, $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel immuno-therapies  Eli Lilly and ImmuNext plan to build a 3yrs. research collaboration supporting the development of preclinical targets for autoimmune diseases by regulating immune cell […]Read More


Celgene Files NDA for Ozanimod to the US FDA for

Shots: The NDA filing is based on P-III SUNBEAM & RADIANCE studies assessing Ozanimod vs Avonex in 1,346 & 1,320 patients with RMS across 21 countries for 12 & 24 mos. respectively In H1’19 Celegene has also filed MAA to EMA for relapsing-remitting multiple sclerosis in adults and plans to develop new therapies for RMS […]Read More


Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded

Shots: HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded library design, synthesis and screening, in identifying small molecules for the treatment of atopic dermatitis HitGen’s DELs is a drug discovery platform including 400B macrocyclic […]Read More


AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin

Shots: Kyowa Kirin to receives upfront, regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan In Mar,2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia Fasenra […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 18-22, 2019)

Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019 Published: March 22, 2019 | Tags: Novartis, Announces, Spin-Off, Alcon, Eye Care, Business, April 9, 2019 Celgene Collaborates with Exscientia for its AI Drug Discovery Platform Published: March 22, 2019 | Tags: Celgene, Collaborates, Exscientia, AI, Drug Discovery Platform Biogen and Eisai Terminate P-III ENGAGE and […]Read More


Eisai Signs a Research Agreement with Cerveau Technologies for its

Shots: Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies Cerveau’s MK-6240 is a […]Read More